Center MM, Jemal A, Smith RA, Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009, 59: 366-378. 10.3322/caac.20038.
Article
PubMed
Google Scholar
Ogino S, Fuchs CS, Giovannucci E: How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012, 12: 621-628. 10.1586/erm.12.46.
Article
CAS
PubMed
PubMed Central
Google Scholar
Boonstra MC, Verspaget HW, Ganesh S, Kubben FJ, Vahrmeijer AL, van de Velde CJ, Kuppen PJ, Quax PH, Sier CF: Clinical applications of the urokinase receptor (uPAR) for cancer patients. Curr Pharm Des. 2011, 17: 1890-1910. 10.2174/138161211796718233.
Article
CAS
PubMed
Google Scholar
Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, Romer J: Plasminogen activation and cancer. Thromb Haemost. 2005, 93: 676-681.
PubMed
Google Scholar
Vassalli JD, Baccino D, Belin D: A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985, 100: 86-92. 10.1083/jcb.100.1.86.
Article
CAS
PubMed
Google Scholar
Schlechte W, Murano G, Boyd D: Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res. 1989, 49: 6064-6069.
CAS
PubMed
Google Scholar
Blasi F, Sidenius N: The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 2010, 584: 1923-1930. 10.1016/j.febslet.2009.12.039.
Article
CAS
PubMed
Google Scholar
Pyke C, Kristensen P, Ralfkiaer E, Grøndahl-Hansen J, Eriksen J, Blasi F, Danø K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 1991, 138: 1059-1067.
CAS
PubMed
PubMed Central
Google Scholar
Sier CF, Quax PH, Vloedgraven HJ, Verheijen JH, Griffioen G, Ganesh S, Lamers CB, Verspaget HW: Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases. Invasion Metastasis. 1993, 13: 277-288.
CAS
PubMed
Google Scholar
Allgayer H: Translational research on u-PAR. Eur J Cancer. 2010, 46: 1241-1251. 10.1016/j.ejca.2010.02.029.
Article
CAS
PubMed
Google Scholar
Hildenbrand R, Schaaf A: The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int J Oncol. 2009, 34: 15-23.
CAS
PubMed
Google Scholar
Illemann M, Bird N, Majeed A, Laerum OD, Lund LR, Danø K, Nielsen BS: Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer. 2009, 124: 1860-1870. 10.1002/ijc.24166.
Article
CAS
PubMed
Google Scholar
Blok EJ, Kuppen PJ, Van Leeuwen JE, Sier CF: Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. Clin Med Insights Oncol. 2013, 7: 41-51.
Article
CAS
PubMed
PubMed Central
Google Scholar
Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, Furie B, Furie BC, Cines DB, Huang M: Structure of human urokinase plasminogen activator in complex with its receptor. Science. 2006, 311: 656-659. 10.1126/science.1121143.
Article
CAS
PubMed
Google Scholar
Grøndahl-Hansen J, Peters HA, Van Putten WL, Look MP, Pappot H, Rønne E, Danø K, Klijn JG, Brünner N, Foekens JA: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res. 1995, 1: 1079-1087.
PubMed
Google Scholar
Kotzsch M, Bernt K, Friedrich K, Luther E, Albrecht S, Gatzweiler A, Magdolen V, Baretton G, Zietz C, Luther T: Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma. Histopathology. 2010, 57: 461-471. 10.1111/j.1365-2559.2010.03644.x.
Article
PubMed
Google Scholar
Kim SJ, Shiba E, Taguchi T, Watanabe T, Tanji Y, Kimoto Y, Izukura M, Takai SI: Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. Anticancer Res. 1997, 17: 1373-1378.
CAS
PubMed
Google Scholar
Giannopoulou I, Mylona E, Kapranou A, Mavrommatis J, Markaki S, Zoumbouli C, Keramopoulos A, Nakopoulou L: The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas. Cancer Lett. 2007, 246: 262-267. 10.1016/j.canlet.2006.03.003.
Article
CAS
PubMed
Google Scholar
Li Y, Parry G, Chen L, Callahan JA, Shaw DE, Meehan EJ, Mazar AP, Huang M: An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope. J Mol Biol. 2007, 365: 1117-1129. 10.1016/j.jmb.2006.10.059.
Article
CAS
PubMed
Google Scholar
Halamkova J, Kiss I, Pavlovsky Z, Jarkovsky J, Tomasek J, Tucek S, Hanakova L, Moulis M, Cech Z, Zavrelova J, Penka M: Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients. Hepatogastroenterology. 2011, 58: 1918-1925.
CAS
PubMed
Google Scholar
Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Andersen J, Overgaard J: Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol. 2008, 47: 591-599. 10.1080/02841860701851871.
Article
CAS
PubMed
Google Scholar
Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987, 8: 138-140.
CAS
PubMed
Google Scholar
Alpizar-Alpizar W, Christensen IJ, Santoni-Rugiu E, Skarstein A, Ovrebo K, Illemann M, Laerum OD: Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma. Int J Cancer. 2012, 131: E329-E336. 10.1002/ijc.26417.
Article
CAS
PubMed
Google Scholar
Ohtani H, Pyke C, Dano K, Nagura H: Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Int J Cancer. 1995, 62: 691-696. 10.1002/ijc.2910620608.
Article
CAS
PubMed
Google Scholar
Otranto M, Sarrazy V, Bonte F, Hinz B, Gabbiani G, Desmouliere A: The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr. 2012, 6: 203-219. 10.4161/cam.20377.
Article
PubMed
PubMed Central
Google Scholar
Erreni M, Mantovani A, Allavena P: Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron. 2011, 4: 141-154. 10.1007/s12307-010-0052-5.
Article
CAS
PubMed
Google Scholar
De Wever O, Demetter P, Mareel M, Bracke M: Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 2008, 123: 2229-2238. 10.1002/ijc.23925.
Article
CAS
PubMed
Google Scholar
Zhang J, Sud S, Mizutani K, Gyetko MR, Pienta KJ: Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia. 2011, 13: 23-30.
Article
PubMed
PubMed Central
Google Scholar
Vong S, Kalluri R: The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. Genes Cancer. 2011, 2: 1139-1145. 10.1177/1947601911423940.
Article
PubMed
PubMed Central
Google Scholar
Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F: The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 1998, 58: 1843-1849.
CAS
PubMed
Google Scholar
Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Danø K, Brünner N: Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst. 1999, 91: 869-874. 10.1093/jnci/91.10.869.
Article
CAS
PubMed
Google Scholar
Lomholt AF, Christensen IJ, Høyer-Hansen G, Nielsen HJ: Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol. 2010, 49: 805-811. 10.3109/0284186X.2010.491086.
Article
CAS
PubMed
Google Scholar
Taubert H, Wurl P, Greither T, Kappler M, Bache M, Lautenschlager C, Fussel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V, Kotzsch M: Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer. 2010, 102: 731-737. 10.1038/sj.bjc.6605520.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kjellman A, Akre O, Gustafsson O, Høyer-Hansen G, Lilja H, Norming U, Piironen T, Tornblom M: Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening. J Intern Med. 2011, 269: 299-305. 10.1111/j.1365-2796.2010.02284.x.
Article
CAS
PubMed
Google Scholar
Almasi CE, Brasso K, Iversen P, Pappot H, Høyer-Hansen G, Danø K, Christensen IJ: Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate. 2011, 71: 899-907. 10.1002/pros.21306.
Article
CAS
PubMed
Google Scholar
Sier CF, Nicoletti I, Lisa SM, Frandsen T, Aletti G, Ferrari A, Lissoni A, Giavazzi R, Blasi F, Sidenius N: Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb Haemost. 2004, 91: 403-411.
CAS
PubMed
Google Scholar
Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA, Mazar AP: An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia. 2010, 12: 778-788.
Article
CAS
PubMed
PubMed Central
Google Scholar
Van Buren G, Gray MJ, Dallas NA, Xia L, Lim SJ, Fan F, Mazar AP, Ellis LM: Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer. 2009, 115: 3360-3368. 10.1002/cncr.24371.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E: Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011, 17: 459-471. 10.1158/1078-0432.CCR-10-2258.
Article
CAS
PubMed
Google Scholar